Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03873402 · ClinicalTrials.gov registry record · Phase 3
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
A Phase 3 study of Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 3
- Development phase
- 437
- Enrollment target
- 20
- Study locations
NCT03873402: Active Phase 3 study of Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb.
NCT03873402 is a Phase 3 study of Renal Cell Carcinoma that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 437 participants, above the 239-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (83% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03873402, a Phase 3 study of Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 437 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test the effectiveness and safety of nivolumab combined with ipilimumab compared to nivolumab monotherapy in participants with previously untreated kidney cancer that has spread.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- OTHER Ipilimumab placebo
Study Locations (20)
Other
- Local Institution - 0005 - Córdoba
- Local Institution - 0002 - San Juan
- Local Institution - 0033 - Graz
- Local Institution - 0031 - Vienna
- Local Institution - 0032 - Wels
Massachusetts
- Local Institution - 0066 - Boston
- Local Institution - 0088 - Boston
- Local Institution - 0086 - Boston
Buenos Aires
- Local Institution - 0100 - Capital Federal
- Local Institution - 0011 - Ciudad Autónoma de Buenos Aires
- Local Institution - 0060 - Mar del Plata
Región de Valparaíso
- Local Institution - 0004 - Viña del Mar
- Local Institution - 0012 - Viña El Mar
District of Columbia
- Local Institution - 0013 - Washington D.C.
Georgia
- Local Institution - 0053 - Athens
Pennsylvania
- The Reading Hosp Med Ctr Reg Cancer Ctr - West Reading
South Carolina
- Local Institution - 0084 - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 437 participants |
| Start Date | 2019-06-21 |
| Est. Completion | 2027-03-11 |
| Phase | Phase 3 |
What the registry record for NCT03873402 still lists
NCT03873402 is an interventional study that assigns participants to a tested intervention. The registered 437 participants enrollment target is mid-sized for trials with a published cap, above the 239-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (83% higher).
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT03873402 names 20 study sites across 11 states, led by Other, Massachusetts, Buenos Aires.
Frequently Asked Questions
What is clinical trial NCT03873402 about?
NCT03873402 is a clinical study titled "A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer". The purpose of this study is to test the effectiveness and safety of nivolumab combined with ipilimumab compared to nivolumab monotherapy in participants with previously untreated kidney cancer that has spread.
What is the current status of trial NCT03873402?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 437 participants. The study started on 2019-06-21. Estimated completion is 2027-03-11.
What conditions does trial NCT03873402 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT03873402?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Ipilimumab placebo (OTHER).
Who is sponsoring clinical trial NCT03873402?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03873402 being conducted?
This trial has 20 study locations across District of Columbia, Georgia, Massachusetts, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03873402's enrollment target sits among peer trials
437 19th of 121 higher than 103 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
RECRUITING · Phase 3
-
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
ACTIVE NOT RECRUITING · Phase 3
-
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05711446 · 438 participants · NA
Double Voiding and Post-transplant UTI
- NCT02622542 · 436 participants · NA
ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy
- NCT05918211 · 436 participants · Phase 3
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
- NCT06966479 · 436 participants · Phase 2
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI